Online inquiry

IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8597MR)

This product GTTS-WQ8597MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FOLH1 gene. The antibody can be applied in Prostate Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2346
UniProt ID Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8597MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6367MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ11371MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ10178MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ11599MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ5407MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ14122MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ12328MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ3754MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-1093884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW